Bioprinted Pediatric Airway Constructs: A Review of Current Evidence and Clinical Implications

Abstract

Bioprinted pediatric airway constructs represent a transformative frontier in the management of congenital and acquired airway defects in children. Leveraging advances in tissue engineering, bioprinting technologies offer patient-specific, functional airway replacements, potentially overcoming the limitations of traditional surgical grafts and prostheses. This review synthesizes current evidence surrounding the development, clinical applications, and future directions of bioprinted airway constructs, highlighting their mechanism-based advantages, relevant risk factors, and implications for pediatric otolaryngology and thoracic surgery.

Introduction

The management of pediatric airway anomalies, including tracheal stenosis, malacia, and segmental defects, remains a significant clinical challenge due to the unique anatomical and physiological considerations in children. Conventional interventions, such as autologous grafts and synthetic stents, are often associated with complications, limited growth potential, and the need for multiple interventions. Bioprinting, an advanced form of additive manufacturing, enables the fabrication of complex, living tissue constructs that mimic native airway architecture and support integration and growth within the pediatric milieu. This review explores the scientific basis, clinical relevance, and future prospects of bioprinted pediatric airway constructs, integrating recent PubMed-indexed literature and guideline recommendations.

Epidemiology / Disease Burden

Pediatric airway disorders, including congenital tracheal stenosis, laryngeal atresia, and acquired injuries, affect an estimated 1 in 10,000 live births. These conditions contribute significantly to neonatal and infant morbidity and mortality, with airway compromise being a leading cause of pediatric intensive care admissions and surgical interventions. The burden of disease is further amplified by the need for repeated procedures and long-term respiratory support, underscoring the need for durable, growth-accommodating airway solutions.

Pathophysiology

Congenital anomalies such as complete tracheal rings, segmental agenesis, and vascular compression disrupt normal airway patency and function. Acquired defects may result from prolonged intubation, infection, trauma, or tumor resection. The pediatric airway's dynamic growth and susceptibility to scarring complicate reconstruction efforts, often leading to restenosis, malacia, or graft failure. Bioprinted constructs are designed to replicate the native extracellular matrix composition and cellular heterogeneity, promoting integration, epithelialization, and functional support.

Risk Factors

Risk factors for pediatric airway pathology include genetic syndromes (e.g., Down syndrome, VACTERL association), prematurity, prolonged mechanical ventilation, previous airway surgeries, and traumatic or infectious insults. Patients with complex comorbidities or extensive defects are particularly challenging candidates for conventional repair, motivating the development of novel bioprinted solutions.

Clinical Features

Children with airway anomalies typically present with stridor, wheeze, cyanosis, recurrent respiratory infections, feeding difficulties, and failure to thrive. Severity depends on the location, length, and degree of airway compromise. Early recognition and multidisciplinary evaluation are critical for optimizing outcomes and planning reconstructive strategies.

Diagnosis

Diagnostic workup includes flexible and rigid bronchoscopy, high-resolution computed tomography (CT), and magnetic resonance imaging (MRI) to delineate airway anatomy and identify associated vascular or parenchymal anomalies. 3D imaging and modeling facilitate preoperative planning and the design of patient-specific bioprinted constructs. Genetic testing and multidisciplinary assessment are often warranted in syndromic or complex cases.

Treatment & Management

Conventional management options encompass balloon dilation, tracheal resection and anastomosis, slide tracheoplasty, and stent placement. However, these approaches are limited by donor tissue availability, graft-host mismatch, immunologic rejection, infection, and the inability to grow with the child. Bioprinted constructs, seeded with autologous or allogeneic cells, aim to overcome these limitations by providing customized, biologically active scaffolds that integrate with host tissue, promote regeneration, and accommodate somatic growth.

Recent Advances / Emerging Therapies

Recent advances in bioprinting technology include the use of biodegradable polymers, hydrogels, and decellularized extracellular matrix as bioinks, combined with patient-derived mesenchymal stem cells or chondrocytes. Layer-by-layer printing strategies enable the creation of anatomically accurate, mechanically stable, and biologically functional airway segments. Preclinical studies in animal models have demonstrated successful implantation, epithelialization, and airway patency over extended follow-up. Early-phase clinical case reports document the feasibility of using bioprinted airway splints in infants with severe tracheobronchomalacia, resulting in life-saving outcomes and improved quality of life. Ongoing trials are evaluating long-term durability, immunogenicity, and integration in larger patient cohorts.

Guideline Recommendations

Professional societies emphasize the importance of multidisciplinary care, individualized preoperative planning, and the integration of advanced imaging and modeling in pediatric airway reconstruction. While bioprinted constructs remain investigational, consensus guidelines endorse their use within regulated clinical trials or compassionate-use protocols for patients with no viable conventional options. Long-term follow-up, robust outcome tracking, and standardization of bioprinting protocols are necessary to facilitate wider clinical adoption.

Conclusion

Bioprinted pediatric airway constructs offer a paradigm shift in the management of complex airway anomalies, with the potential to provide durable, patient-specific, and functionally integrated replacements. While early evidence is promising, further research is required to optimize scaffold design, cellular composition, and regulatory standards. Collaborative efforts between clinicians, engineers, and regulatory bodies will be essential to realize the full therapeutic potential of this emerging technology, ultimately improving outcomes for children with otherwise intractable airway disease.